Informações:
Falhas:
ID
46172
Descrição
Principal Investigator: Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA MeSH: Prostatic Neoplasms,Neutropenia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001002 The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA
Link
Palavras-chave
Versões (2)
- 09/11/2023 09/11/2023 - Simon Heim
- 29/01/2025 29/01/2025 - Akane Nishihara
Titular dos direitos
Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA
Transferido a
29 de janeiro de 2025
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
Eligibility Criteria
- StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Similar models
Eligibility Criteria
- StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,2])
CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.
Item
CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.
boolean
C5419021 (UMLS CUI [1,1])
C4721208 (UMLS CUI [1,2])
C0332168 (UMLS CUI [1,3])
C0021430 (UMLS CUI [2,1])
C1709519 (UMLS CUI [2,2])
C5418944 (UMLS CUI [2,3])
C0012854 (UMLS CUI [2,4])
C1285573 (UMLS CUI [2,5])
C4721208 (UMLS CUI [1,2])
C0332168 (UMLS CUI [1,3])
C0021430 (UMLS CUI [2,1])
C1709519 (UMLS CUI [2,2])
C5418944 (UMLS CUI [2,3])
C0012854 (UMLS CUI [2,4])
C1285573 (UMLS CUI [2,5])
Sem comentários